BioCryst製藥 BCRX 深 滬
已收盤 09-05 16:00:00 美东时间
8.27
0.000
0.00%
華盛通- 最 高8.355
- 今 開8.27
- 成交量 308.67万股
- 最 低 8.14
- 昨 收 8.27
- 總市值 17.28亿
- 52周最高 11.31
- 市盈率 靜 --
- 換手率 1.48%
- 52周最低 6.015
- 委 比 -39.79%
- 總股本 2.09亿
- 歷史最高 19.99
- 量 比 1.28
- 振 幅 2.60%
- 歷史最低 1.08
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
Peter Altman, PhD., President and CEO of BioCardia, Inc., will present a corporate update at the H. C. Wainwright 27th Annual Global Investment Conference in New York City on September 10, 2025. His presentation will include recent progress on the company’s clinical cell therapy programs for ischemic heart disease, regulatory activities for CardiAMP® cell therapy and the Helix™ delivery catheter, and updates on partnerships and funding for the Ca...
09-04 13:00
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
08-22 02:24
BioCryst’s Chief R&D Officer Resigns Amid CEO Decision
The latest announcement is out from BioCryst ( ($BCRX) ). On August 6, 2025, Dr...
08-11 19:29
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
BioCardia, Inc., a developer of cellular therapies for cardiovascular and pulmonary diseases, reported second-quarter 2025 financial results, including increased R&D expenses, lower SG&A costs, and a net loss of $2.0 million. The company highlighted progress with its CardiAMP autologous cell therapy, including successful Phase 3 trial results and ongoing submissions to Japan's PMDA and the FDA. They are also advancing the CardiAMP HF II trial and...
08-11 13:15
BioCryst Announces Departure of Dr. Helen Thackray
Dr. Helen Thackray, BioCryst Pharmaceuticals' chief research and development officer, will depart on September 1, 2025, transitioning to an advisory role until year-end. Thackray has contributed significantly to the company, including advancing several programs such as the KLK5 inhibitor and avoralstat. CEO Jon Stonehouse expressed gratitude for her work and wished her well in her new leadership role. BioCryst remains focused on advancing therapi...
08-11 11:00
美股大行评级 | 潜在涨幅123.33%！Maxim Group上调优利系统目标价至9美元，评级升至"买入"
今日重点评级关注：Maxim Group：上调优利系统评级至"买入"，目标价9美元；Canaccord Genuity：维持Enovix"买入"评级，目标价从20美元升至22美元
08-05 08:35
Needham Maintains Buy on BioCryst Pharma, Maintains $17 Price Target
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $17 price target.
08-05 06:11
BioCryst Pharma Maintains FY25 Outlook For Global Net ORLADEYO Revenue Between $580M And $600M
Financial Outlook for 2025The company is maintaining its outlook for full year 2025 global net ORLADEYO revenue to between $580 million and $600 million, even when excluding fourth quarter European revenue after the
08-04 19:05
BioCryst Pharma Q2 EPS $0.02 Misses $0.04 Estimate, Sales $163.353M Beat $149.530M Estimate
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.04 by 45.95 percent. This is a 133.33 percent increase over losses of $(0.06) per share from
08-04 19:01
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
